A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer

(2015) Harminder S. Takhar et al.   ANTI-CANCER DRUGS

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

(2015) Sarah Frys et al.   BRITISH JOURNAL OF HAEMATOLOGY

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

(2015) Assuntina G. Sacco et al.   JOURNAL OF CLINICAL ONCOLOGY

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

(2014) S Bauer et al.   BRITISH JOURNAL OF CANCER

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

(2014) J. E. Gray et al.   CLINICAL CANCER RESEARCH

Histone modifications contribute to cellular replicative and hydrogen peroxide-induced premature senescence in human embryonic lung fibroblasts

(2014) Wenjuan Zhang et al.   FREE RADICAL RESEARCH

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

(2013) Tianzhu Qiu et al.   Future Oncology

Oncogene-induced cellular senescence elicits an anti-Warburg effect

(2013) Mingxi Li et al.   PROTEOMICS

Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic Defects

(2013) Michael Prystowsky et al.   Scientific Reports

Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro

(2012) Hongtu Chao et al.   CANCER LETTERS

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

(2012) Yu Sun et al.   NATURE MEDICINE

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

(2012) Missak Haigentz et al.   ORAL ONCOLOGY

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

(2011) Tae-Won Kang et al.   NATURE

Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders

(2011) Darren J. Baker et al.   NATURE

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo

(2011) Valentina Zuco et al.   PLoS One

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis

(2010) Roy Sidi et al.   EUROPEAN JOURNAL OF CANCER

In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?

(2010) Susan C. Modesitt et al.   GYNECOLOGIC ONCOLOGY

Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent

(2010) S. K. Chao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Senescence-Associated Oxidative DNA Damage Promotes the Generation of Neoplastic Cells

(2009) K. Gosselin et al.   CANCER RESEARCH

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

(2009) P. Munster et al.   CLINICAL CANCER RESEARCH

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY